EPRX Share Price Performance

EPRX Community Fair Values

View all narratives

Recent EPRX News & Updates

No updates

Eupraxia Pharmaceuticals Inc. Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

n/a

Earnings per share (EPS): -0.76
Gross Margin: 0%
Net Profit Margin: 0%
Debt/Equity Ratio: 0%

View full report ›

Eupraxia Pharmaceuticals Inc. Competitors

About EPRX

Founded: 2011
Employees: 33
CEO: James Helliwell
WebsiteView website: www.eupraxiapharma.com

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company’s proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Canadian Market Performance

0.8%

12.7%

17.9%

10.2%

In the last week, the market has been flat, with a notable exception in the Healthcare sector dropping 3.7%. Meanwhile, the market is actually up 18% over the past year. Earnings are forecast to grow by 12% annually. Market details ›

Eupraxia Pharmaceuticals Stock Price

EPRX Share Price Performance

EPRX Community Fair Values

Recent EPRX News & Updates

Eupraxia Pharmaceuticals Inc. Key Details

Eupraxia Pharmaceuticals Inc. Competitors

St. Davids Capital

Little Fish Acquisition I

Castlebar Capital

Pardus Ventures

Haw Capital 2

Shine Box Capital

Mandeville Ventures

Canna 8 Investment Trust

🇪🇺 🇬🇧 Momentum Is Returning to European and UK Markets

The Big Beautiful Deficit